Active Ingredient(s):Cemiplimab-rwlc FDA Approved: * September 28, 2018 Pharm Company: *REGENERON PHARMACEUTICALS Category:Cancer
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.
In September 2018, it was appr...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion